Study of the Prognostic Impact of CD44 on Renal Cell Carcinoma
ConditionRenal Cell Cancer
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorAssiut University
About this trial
1. Study the expression of CD44 in various histopathological types of RCC. 2. Study the association between CD44 expression and other clinicopathological parameters 3. study the impact of CD44 expressions in tumor and patients' survival
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
patient must be more than 18 years
Patients with complete pathological data
Disqualifiers
The presence of any other organ malignancies
Patients who lost follow-up after nephrectomy less than 3-year,
Patients with incomplete pathological data
Trial population
patients with RCC who had undergone radical or partial nephrectomy, between 2014 and 2019.
Trial design
Design model
Case-control
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Study of the prognostic impact of CD44 on renal cell carcinoma.
assess the expression of CD44 in various histopathological types of RCC. understanding their biology is mandatory to define novel potential prognostic and therapeutic targets for all RCC subtypes.
Time frame
BaselineLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: